US FDA questions about the adequacy of efficacy evidence for tazemetostat come amid concerns about the risk of secondary malignancies. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
